Corporate Member Update: Pfizer-BAVENCIO®

Corporate Member Update: Pfizer-BAVENCIO®

BAVENCIO®
July, 2020

Pfizer is pleased to announce that on June 30, 2020 the U.S. Food and Drug Administration (FDA) approved BAVENCIO® (avelumab) Injection 20 mg/mL for a new indication.  BAVENCIO is co-developed and co-commercialized by EMD Serono and Pfizer Inc.

Please  refer to the revised  Full Prescribing Information for BAVENCIO.

 

 
 
Become a NOS Member Today!
 

Platinum Corporate Members

Gold Corporate Members